AI assistant
Nuvectis Pharma, Inc. — Director's Dealing 2025
Jun 20, 2025
33912_dirs_2025-06-20_6965c3c2-f96d-4412-b761-ead9e2e5c94e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2025-06-17
Reporting Person: Mosseri Marlio Charles (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-17 | Common Stock | P | 5399 | $8.11 | Acquired | 2948160 | Indirect |
| 2025-06-18 | Common Stock | P | 28043 | $8.05 | Acquired | 2976203 | Indirect |
Footnotes
F1: Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL.
F2: Reflects the weighted average purchase price. The range of prices for the shares purchased was $7.91 to $8.11. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.